Cancer drug setbacks disappoint, but access deals hold out promise
This article was originally published in Scrip
Executive Summary
The past month has seen some disappointments for European cancer patients, with the EU's first potential gene therapy product, Cerepro, and the VEGF-targeting antibody, Avastin, both being turned down for use in brain cancers.